| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6175194 | European Urology | 2015 | 9 Pages |
Abstract
Inactivation of the PTEN gene is a common event promoting prostate cancer (PCa) progression. This preclinical study illustrates the potent anticancer activity of novel PTEN-targeted drugs on PCa models, particularly in combination with hormonal therapy.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Rute B. Marques, Ashraf Aghai, Corrina M.A. de Ridder, Debra Stuurman, Sander Hoeben, Agnes Boer, Rebecca P. Ellston, Simon T. Barry, Barry R. Davies, Jan Trapman, Wytske M. van Weerden,